Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 9/20 | 0.53 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 2/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | DRD1 | P21728 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | DRD5 | P21918 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29709485 | 0.94 | PARP1 (0.60) | PARP1PARP2DRD3DRD2 | |
| SCHEMBL6028914 | 0.94 | PARP1 (0.60) | PARP1PARP2DRD3DRD2 | |
| SCHEMBL6028177 | 0.85 | PARP1 (0.56) | PARP1PARP2 | |
| SCHEMBL5076303 | 0.83 | PARP1 (0.55) | PARP1PARP2AURKAAURKBHTR1A | |
| SCHEMBL6028534 | 0.82 | PARP1 (0.48) | PARP1DRD4DRD3DRD2 | |
| SCHEMBL6029106 | 0.80 | PARP1 (0.58) | PARP1PARP2 | |
| Hydrochloric Acid SCHEMBL18614327 | 0.80 | PARP1 (0.62) | PARP1PARP2AURKAAURKB | |
| SCHEMBL8818276 | 0.78 | HRH3 (0.45) | HTR1ADRD1DRD4DRD5DRD3 | |
| SCHEMBL5621656 | 0.78 | PARP1 (0.62) | PARP1PARP2AURKAAURKB | |
| SCHEMBL6028492 | 0.78 | PDPK1 (0.44) | PARP1AURKABTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7087637-B2 | Substituted indoles which are PARP inhibitors | BASF AG (DE) | 2006-08-08 | — | — | US | disclosed |
| US-20040067949-A1 | Substituted indoles which are parp inhibitors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067949-A1 | Substituted indoles which are parp inhibitors | PARP1, PARP2, PARP12 | PARP1 1/4885PARP2 2/4885AURKA 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.